• 1
    Goldstein E, Kirkcaldy RD, Reshef D, et al. Factors related to increasing prevalence of resistance to ciprofloxacin and other antimicrobial drugs in Neisseria gonorrhoeae, United States. Emerg Infect Dis 2012; 18:12901297.
  • 2
    Schwab L, Tizazu T. Destructive epidemic Neisseria gonorrhoeae keratoconjunctivitis in African adults. Br J Ophthalmol 1985; 69:525528.
  • 3
    Guerrero ML, Alfaro IJ, Sandoval BG, et al. “Ophthalmia Venerea”: a dreadful complication of fluoroquinolone-resistant Neisseria gonorrhoeae. Sex Transm Dis 2010; 37:340341.
  • 4
    Meyer-Rüsenberg B, Loderstädt U, Richard G, et al. Epidemic keratoconjunctivitis: the current situation and recommendations for prevention and treatment. Dtsch Arztebl Int 2011; 108:475480.
  • 5
    Heim A, Ebnet C, Harste G, et al. Rapid and quantitative detection of human adenovirus DNA by real-time PCR. J Med Virol 2003; 70:228239.
  • 6
    Madisch I, Harste G, Pommer H, et al. Phylogenetic analysis of the main neutralization and hemagglutination determinants of all human adenovirus prototypes as a basis for molecular classification and taxonomy. J Virol 2005; 79:1526515276.
  • 7
    Aoki K, Ishiko H, Konno T, et al. Epidemic keratoconjunctivitis due to the novel hexon-chimeric-intermediate 22,37/H8 human adenovirus. J Clin Microbiol 2008; 46:32593269.
  • 8
    Kaneko H, Aoki K, Ishida S, et al. Recombination analysis of intermediate human adenovirus type 53 in Japan by complete genome sequence. J Gen Virol 2011; 92:12511259.
  • 9
    Kestelyn P, Bogaerts J, Meheus A. Gonorrheal keratoconjunctivitis in African adults. Sex Transm Dis 1987; 14:191194.
  • 10
    Trees DL, Sirivongrangson P, Schultz AJ, et al. Multiclonal increase in ciprofloxacin-resistant Neisseria gonorrhoeae, Thailand, 1998–1999. Sex Transm Dis 2002; 29:668673.
  • 11
    Srifeungfung S, Roongpisuthipong A, Asavapiriyanont S, et al. Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae in HIV-seropositive patients and gonococcal antimicrobial susceptibility: an update in Thailand. Jpn J Infect Dis 2009; 62:467470.
  • 12
    Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR Morb Mortal Wkly Rep 2010; 59:12.
  • 13
    Wang SA, Lee MV, O'Connor N, et al. Multidrug-resistant Neisseria gonorrhoeae with decreased susceptibility to cefixime—Hawaii, 2001. Clin Infect Dis 2003; 37:84952.
  • 14
    Haimovici R, Roussel TJ. Treatment of gonococcal conjunctivitis with single-dose intramuscular ceftriaxone. Am J Ophthalmol 1989; 107:511514.
  • 15
    Babushkin AE. [A case of epidemic keratoconjunctivitis complicated by gonococcal infection]. [Article in Russian]. Vestn Oftalmol 2001; 117:5253.
  • 16
    Ford E, Nelson KE, Warren D. Epidemiology of epidemic keratoconjunctivitis. Epidemiol Rev 1987; 9:244261.
  • 17
    Engelmann I, Madisch I, Pommer H, et al. An outbreak of epidemic keratoconjunctivitis caused by a new intermediate adenovirus 22/H8 identified by molecular typing. Clin Infect Dis 2006; 43:e64e66.
  • 18
    Kaneko H, Suzutani T, Aoki K, et al. Epidemiological and virological features of epidemic keratoconjunctivitis due to new human adenovirus type 54 in Japan. Br J Ophthalmol 2011; 95:3236.
  • 19
    Nakamura M, Hirano E, Kowada K, et al. Surveillance of adenovirus D in patients with epidemic keratoconjunctivitis from Fukui Prefecture, Japan, 1995–2010. J Med Virol 2012; 84:8186.
  • 20
    Kanski J. Clinical ophthalmology, a systematic approach. 4th. Ed. Oxford: Butterworth Heinemann, 1999.